2
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
9
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Multiple Myeloma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Radiation Injuries
2
Prostatic Neoplasms
2
Preleukemia
2
Precancerous Conditions
2
Osteosarcoma
2
Neoplasms by Histologic Type
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Multiple Chronic Conditions
2
Melanoma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia, Lymphoid
2
Leukemia, Biphenotypic, Acute
2
Interventions
Carboplatin
19
Pemetrexed
10
Paclitaxel
7
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
Bronchoscopy
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Drug Delivery Systems
2
Docetaxel
2
Blood Specimen Collection
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
toripalimab
1
taletrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
Patient Reported Outcome Measures
×
Clear all
NCT03053297
2018-02-08
PANORAMA
AstraZeneca
Terminated
89 enrolled